-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Reiterates Buy on Altimmune, Lowers Price Target to $11

Benzinga·11/13/2026 14:19:18
Listen to the news
B. Riley Securities analyst William Woods reiterates Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $13 to $11.